Assessing Schizophrenia-Relevant Cognitive and Social Deficits in Mice: A selection of Mouse behavioral Tasks and Potential Therapeutic Compounds

Current Pharmaceutical Design

Volumn 20, Issue 32, 2014, Pages 5127-5138

  Lai, Wen Sung ^a   Chang, Chia Yuan ^a   Wong, Wan Rong ^a   Pei, Ju Chun ^a   Chen, Ya Shan ^a   Hung, Wei Li ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Attention; Choice behavior; Cognitive social deficit; Glutamate hypothesis of schizophrenia; Glycine; Mouse behavioral tasks; Schizophrenia; Social communication

Indexed keywords

CYCLOSERINE; DEXTRO SERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SARCOSINE; NOOTROPIC AGENT;

5 CHOICE SERIAL REACTION TIME TASK; ARTICLE; ATTENTION; BEHAVIOR DISORDER; COGNITIVE DEFECT; DECISION MAKING; DYNAMIC FORAGING TASK; EXPERIMENTAL SOCIAL BEHAVIOR TEST; EXPLORATORY BEHAVIOR TEST; FOOD PREFERENCE; FOOD PREFERENCE TASK; FORAGING; GENETIC MODEL; HOLE BOARD TEST; INTERPERSONAL COMMUNICATION; LEARNING; MAZE TEST; MOLECULAR PATHOLOGY; MOUSE MODEL; NEGATIVE SYNDROME; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; PRIORITY JOURNAL; RESPONSE TIME; SCHIZOPHRENIA; SOCIAL DEFICIT; ULTRASONIC VOCALIZATION TASK; ANIMAL; ANIMAL BEHAVIOR; COGNITION DISORDERS; DISEASE MODEL; HUMAN; METABOLISM; MOUSE; PATHOPHYSIOLOGY; REPRODUCIBILITY; SOCIAL BEHAVIOR; COGNITION ASSESSMENT; EXPERIMENTAL BEHAVIORAL TEST; FORAGING BEHAVIOR; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; PATHOGENESIS; POSITIVE SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SOCIAL DISABILITY; SOCIAL STATUS; TASK PERFORMANCE; ULTRASONIC VOCALIZATION; VOCALIZATION;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NOOTROPIC AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 84965092717     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666140110122750     Document Type: Article

References (151)

1. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-93.
2. Abbott A. Schizophrenia: The drug deadlock. Nature 2010; 468: 158-9.
3. Gogos JA, Gerber DJ. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sci 2006; 27: 226-33.
4. Karayiorgou M, Gogos JA. Schizophrenia genetics: uncovering positional candidate genes. Eur J Hum Genet 2006; 14: 512-9.
5. Lewis CM, Levinson DF, Wise LH, et al. Genome scan metaanalysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003; 73: 34-48.
6. Schwab SG, Wildenauer DB. Update on key previously proposed candidate genes for schizophrenia. Curr Opin Psychiatry 2009; 22: 147-53.
7. Levy RJ, Xu B, Gogos JA, Karayiorgou M. Copy number variation and psychiatric disease risk. Methods Mol Biol 2012; 838: 97-113.
8. Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry 2010; 167: 899-914.
9. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008; 40: 880-5.
10. Bergen SE, Petryshen TL. Genome-wide association studies of schizophrenia: does bigger lead to better results? Curr Opin Psychiatry 2012; 25: 76-82.
11. Luo X, Huang L, Jia P, Li M, Su B, Zhao Z, Gan L. Protein-Protein Interaction and Pathway Analyses of Top Schizophrenia Genes Reveal Schizophrenia Susceptibility Genes Converge on Common Molecular Networks and Enrichment of Nucleosome (Chromatin) Assembly Genes in Schizophrenia Susceptibility Loci. Schizophr Bull 2014; 40: 39-49.
12. Shi J, Levinson DF, Duan J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-7.
13. Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969-76.
14. Bousman CA, Glatt SJ, Everall IP, Tsuang MT. Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1025-49.
15. Ikeda M, Iwata N, Suzuki T, et al. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int J Neuropsychopharmacol 2006; 9: 77-81.
16. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2009; 90: 285-326.
17. Meyer U, Schwendener S, Feldon J, Yee BK. Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res 2006; 173: 243-57.
18. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000; 14: 1-21.
19. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
20. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009; 122: 150-202.
21. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004; 72: 41-51.
22. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72: 29-39.
23. Arguello PA, Gogos JA. Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci 2012; 35: 3-13.
24. Karayiorgou M, Flint J, Gogos JA, Malenka RC. The best of times, the worst of times for psychiatric disease. Nat Neurosci 2012; 15: 811-2.
25. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4-15.
26. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
27. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40: 881-4.
28. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012; 100: 665-77.
29. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006; 14: 669-80.
30. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron 2006; 52: 179-96.
31. Kellendonk C, Simpson EH, Kandel ER. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci 2009; 32: 347-58.
32. Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 2006; 59: 1198-207.
33. Waddington JL, Corvin AP, Donohoe G, O'Tuathaigh CM, Mitchell KJ, Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiatr Clin North Am 2007; 30: 365-99.
34. Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 2009; 32: 485-95.
35. Arguello PA, Markx S, Gogos JA, Karayiorgou M. Development of animal models for schizophrenia. Dis Model Mech 2010; 3: 22-6.
36. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci 2009; 10: 519-29.
37. Chadman KK, Yang M, Crawley JN. Criteria for validating mouse models of psychiatric diseases. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1-11.
38. Gioia D. Understanding the Ecological Validity of Neuropsychological Testing Using an Ethnographic Approach. Qualitative Health Research 2009; 19: 1495-1503.
39. Chaytor N, Schmitter-Edgecombe M. The ecological validity of neuropsychological tests: A review of the literature on everyday cognitive skills. Neuropsychology Review 2003; 13: 181-97.
40. Arguello PA, Gogos JA. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull 2010; 36: 289-300.
41. Carter CS, Barch DM, Buchanan RW, et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 2008; 64: 4-10.
42. Chen YC, Lai WS. Behavioural phenotyping of dopamine transporter knockdown mice using local small interference RNA. Behav Brain Res 2010; 214: 475-9.
43. Chen YW, Lai WS. Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sexspecific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics. Neuroscience 2011; 174: 178-189.
44. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999; 835: 18-26.
45. Takao K, Miyakawa T. Investigating gene-to-behavior pathways in psychiatric disorders: the use of a comprehensive behavioral test battery on genetically engineered mice. Ann N Y Acad Sci 2006; 1086: 144-59.
46. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 2010; 11: 490-502.
47. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010; 36: 246-70.
48. Pierce RC, Kalivas PW. Locomotor behavior. Curr Protoc Neurosci 2007; Chapter 8: Unit 8 1.
49. Lai WS, Xu B, Westphal KG, et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 2006; 103: 16906-11.
50. Harms LR, Eyles DW, McGrath JJ, Mackay-Sim A, Burne TH. Developmental vitamin D deficiency alters adult behaviour in 129/SvJ and C57BL/6J mice. Behav Brain Res 2008; 187: 343-50.
51. Kliethermes CL, Crabbe JC. Pharmacological and genetic influences on hole-board behaviors in mice. Pharmacol Biochem Behav 2006; 85: 57-65.
52. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990; 16: 97-110.
53. Tsuchida K, Ujike H, Kanzaki A, Fujiwara Y, Akiyama K. Ontogeny of enhanced striatal dopamine release in rats with methamphetamine-induced behavioral sensitization. Pharmacol Biochem Behav 1994; 47: 161-9.
54. Chen YW, Kao HY, Min MY, Lai WS. A Sex-and Region-Specific Role of Akt1 in the Modulation of Methamphetamine-Induced Hyperlocomotion and Striatal Neuronal Activity: Implications in Schizophrenia and Methamphetamine-Induced Psychosis. Schizophr Bull 2014; 40: 388-98.
55. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986; 396: 157-98.
56. Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. American Journal of Psychiatry 2003; 160: 815-824.
57. Sankoorikal GM, Kaercher KA, Boon CJ, Lee JK, Brodkin ES. A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry 2006; 59: 415-23.
58. Chen YC, Chen YW, Hsu YF, et al. Akt1 deficiency modulates reward learning and reward prediction error in mice. Genes Brain Behav 2012; 11: 157-69.
59. Nestler EJ, Gould E, Manji H, et al. Preclinical models: Status of basic research in depression. Biol Psychiatry 2002; 52: 503-528.
60. Bannon AW, Malmberg AB. Models of nociception: hot-plate, tailflick, and formalin tests in rodents. Curr Protoc Neurosci 2007; Chapter 8: Unit 8 9.
61. Berridge KC. Measuring hedonic impact in animals and infants: microstructure of affective taste reactivity patterns. Neurosci Biobehav Rev 2000; 24: 173-98.
62. Barch DM. The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 2005; 1: 321-53.
63. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007; 31: 673-704.
64. Morris RGM. Spatial Localization Does Not Require the Presence of Local Cues. Learning and Motivation 1981; 12: 239-260.
65. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001; 36: 60-90.
66. Bouton ME, Bolles RC. Conditioned Fear Assessed by Freezing and by the Suppression of 3 Different Baselines. Animal Learning Behavior 1980; 8: 429-34.
67. Fanselow MS. What Is Conditioned Fear. Trends Neurosci 1984; 7: 460-2.
68. Gogos JA, Morgan M, Luine V, et al. Catechol-Omethyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991-6.
69. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987; 13: 643-68.
70. Shu W, Cho JY, Jiang Y, et al. Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. Proc Natl Acad Sci USA 2005; 102: 9643-8.
71. Fischer J, Hammerschmidt K. Ultrasonic vocalizations in mouse models for speech and socio-cognitive disorders: insights into the evolution of vocal communication. Genes Brain Behav 2011; 10: 17-27.
72. Scattoni ML, Crawley J, Ricceri L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci Biobehav Rev 2009; 33: 508-15.
73. Takahashi N, Kashino M, Hironaka N. Structure of rat ultrasonic vocalizations and its relevance to behavior. PLoS One 2010; 5: e14115.
74. Portfors CV. Types and functions of ultrasonic vocalizations in laboratory rats and mice. J Am Assoc Lab Anim Sci 2007; 46: 28-34.
75. Lahvis GP, Alleva E, Scattoni ML. Translating mouse vocalizations: prosody and frequency modulation. Genes Brain Behav 2011; 10: 4-16.
76. Wang H, Liang S, Burgdorf J, Wess J, Yeomans J. Ultrasonic vocalizations induced by sex and amphetamine in M2, M4, M5 muscarinic and D2 dopamine receptor knockout mice. PLoS One 2008; 3: e1893.
77. Roullet FI, Wohr M, Crawley JN. Female urine-induced male mice ultrasonic vocalizations, but not scent-marking, is modulated by social experience. Behav Brain Res 2011; 216: 19-28.
78. Hammerschmidt K, Radyushkin K, Ehrenreich H, Fischer J. Female mice respond to male ultrasonic 'songs' with approach behaviour. Biol Lett 2009; 5: 589-92.
79. Holy TE, Guo Z. Ultrasonic songs of male mice. PLoS Biol 2005; 3: e386.
80. Scattoni ML, Gandhy SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PLoS One 2008; 3: e3067.
81. Branchi I, Santucci D, Puopolo M, Alleva E. Neonatal behaviors associated with ultrasonic vocalizations in mice (mus musculus): A slow-motion analysis. Dev Psychobiol 2004; 44: 37-44.
82. D'Amato FR, Scalera E, Sarli C, Moles A. Pups call, mothers rush: does maternal responsiveness affect the amount of ultrasonic vocalizations in mouse pups? Behav Genet 2005; 35: 103-12.
83. Hahn ME, Lavooy MJ. A review of the methods of studies on infant ultrasound production and maternal retrieval in small rodents. Behav Genet 2005; 35: 31-52.
84. Liu RC, Miller KD, Merzenich MM, Schreiner CE. Acoustic variability and distinguishability among mouse ultrasound vocalizations. J Acoust Soc Am 2003; 114: 3412-22.
85. Barron S, Gilbertson R. Neonatal ethanol exposure but not neonatal cocaine selectively reduces specific isolation-induced vocalization waveforms in rats. Behav Genet 2005; 35: 93-102.
86. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011; 69: 26R-33R.
87. Baharnoori M, Bhardwaj SK, Srivastava LK. Neonatal behavioral changes in rats with gestational exposure to lipopolysaccharide: a prenatal infection model for developmental neuropsychiatric disorders. Schizophr Bull 2012; 38: 444-56.
88. Wohr M, Schwarting RK. Affective communication in rodents: ultrasonic vocalizations as a tool for research on emotion and motivation. Cell Tissue Res 2013.
89. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31-46.
90. Chen WJ, Faraone SV. Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am J Med Genet 2000; 97: 52-7.
91. Gur RE, Calkins ME, Gur RC, et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 2007; 33: 49-68.
92. Chudasama Y, Robbins TW. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl) 2004; 174: 86-98.
93. Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983; 9: 361-80.
94. Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002; 163: 362-80.
95. Humby T, Laird FM, Davies W, Wilkinson LS. Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. European Journal of Neuroscience 1999; 11: 2813-23.
96. Bari A, Dalley JW, Robbins TW. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 2008; 3: 759-67.
97. Humby T, Wilkinson L, Dawson G. Assaying aspects of attention and impulse control in mice using the 5-choice serial reaction time task. Curr Protoc Neurosci 2005; Chapter 8: Unit 8 5H.
98. Sanchez-Roige S, Pena-Oliver Y, Stephens DN. Measuring impulsivity in mice: the five-choice serial reaction time task. Psychopharmacology 2012; 219: 253-70.
99. Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: A deficit in the representation of value. Schizophr Bull 2008; 34: 835-47.
100. Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry 2007; 62: 756-64.
101. Ragland JD, Cohen NJ, Cools R, Frank MJ, Hannula DE, Ranganath C. CNTRICS imaging biomarkers final task selection: Long-term memory and reinforcement learning. Schizophr Bull 2012; 38: 62-72.
102. Glimcher PW. Quantification of Behavior Sackler Colloquium: Understanding dopamine and reinforcement learning: The dopamine reward prediction error hypothesis. Proc Natl Acad Sci USA 2011; 108: 15647-54.
103. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006; 29: 409-16.
104. Rutledge RB, Lazzaro SC, Lau B, Myers CE, Gluck MA, Glimcher PW. Dopaminergic Drugs Modulate Learning Rates and Perseveration in Parkinson's Patients in a Dynamic Foraging Task. J Neurosci 2009; 29: 15104-14.
105. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997; 275: 1593-9.
106. Fletcher PC, Frith CD. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009; 10: 48-58.
107. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79: 59-68.
108. Corlett PR, Murray GK, Honey GD, et al. Disrupted predictionerror signal in psychosis: evidence for an associative account of delusions. Brain 2007; 130: 2387-400.
109. Murray GK, Corlett PR, Clark L, et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular Psychiatry 2008; 13: 267-76.
110. Sutton R, Barto A. Reinforcement learning: an introduction. MIT Press: Cambridge, M.A. 1998.
111. Kaelbling L, Littman M, Moore A. Reinforcement learning: A survey. Journal of artificial intelligence research 1996; 4: 102-38.
112. Baum W. On two types of deviation from the matching law: Bias and undermatching. J Exp Analysis Behavior 1974; 22: 231.
113. Clements JD, Westbrook GL. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-d-aspartate receptor. Neuron 1991; 7: 605-13.
114. Thomson AM, Walker VE, Flynn DM. Glycine enhances NMDAreceptor mediated synaptic potentials in neocortical slices. Nature 1989; 338: 422-4.
115. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-76.
116. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987; 7: 357-68.
117. Hashimoto A, Kumashiro S, Nishikawa T, et al. Embryonic Development and Postnatal Changes in Free d-Aspartate and d-Serine in the Human Prefrontal Cortex. Journal of Neurochemistry 1993; 61: 348-51.
118. Hashimoto A, Nishikawa T, Oka T, Takahashi K. Endogenous d-Serine in Rat Brain: N-Methyl-d-Aspartate Receptor-Related Distribution and Aging. Journal of Neurochemistry 1993; 60: 783-6.
119. Nagata Y, Horiike K, Maeda T. Distribution of freed-serine in vertebrate brains. Brain Research 1994; 634: 291-5.
120. Schell MJ, Brady Jr. RO, Molliver ME, Snyder SH. d-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors. J Neurosci 1997; 17: 1604-15.
121. Bado P, Madeira C, Vargas-Lopes C, et al. Effects of low-dose Dserine on recognition and working memory in mice. Psychopharmacology (Berl) 2011; 218: 461-70.
122. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidineinduced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008; 18: 414-21.
123. Kanahara N, Shimizu E, Ohgake S, et al. Glycine and D-serine, but not D-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) 2008; 198: 363-74.
124. Karasawa J, Hashimoto K, Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008; 186: 78-83.
125. Lipina T, Labrie V, Weiner I, Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 2005; 179: 54-67.
126. Nilsson M, Carlsson A, Carlsson ML. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 1997; 104: 1195-205.
127. Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010; 209: 263-70.
128. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004; 29: 1080-90.
129. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005; 57: 577-85.
130. Lane HY, Chang Y, Liu Y, Chiu C, Tsai GE. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Archives General Psychiatry 2005; 62: 1196-204.
131. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-60.
132. Tsai GE, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-9.
133. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-5.
134. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of Nmethyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 1998; 95: 15730-4.
135. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003; 89: 691-703.
136. Manahan-Vaughan D, Wildforster V, Thomsen C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). European Journal of Neuroscience 2008; 28: 1342-50.
137. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-9.
138. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 9-12.
139. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 1990; 510: 158-60.
140. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991; 30: 1167-71.
141. Dravid SM, Burger PB, Prakash A, et al. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci 2010; 30: 2741-54.
142. Nakatani-Pawlak A, Yamaguchi K, Tatsumi Y, Mizoguchi H, Yoneda Y. Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol Pharm Bull 2009; 32: 1576-83.
143. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-7.
144. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002; 159: 480-2.
145. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. Dcycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-30.
146. Goff DC, Henderson DC, Evins AE, Amico E. A placebocontrolled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-4.
147. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179: 144-50.
148. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of Dcycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239-48.
149. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 2009; 23(2): 177-89.
150. Pichat P, Bergis OE, Terranova J-P, Urani A, Duarte C, Santucci V, Gueudet C, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007; 32(1): 17-34.
151. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G, Chen G, et al. The Female Urine Sniffing Test: A Novel Approach for Assessing Reward-Seeking Behavior in Rodents. Biol Psychiatry 2011; 67(9): 864-871.